See the DrugPatentWatch profile for bosulif

Exploring the Patent Landscape of Bosulif: Therapeutic Uses and Beyond

As a targeted therapy, Bosulif (bosutinib) has revolutionized the treatment of chronic lymphocytic leukemia (CLL) and other blood cancers. Developed by Pfizer, Bosulif has been approved by regulatory authorities worldwide for its ability to inhibit the activity of BCR-ABL and SRC family kinases. But have you ever wondered about the patents related to Bosulif's therapeutic uses? In this article, we'll delve into the patent landscape of Bosulif and explore its potential applications beyond its approved indications.

Patent Landscape of Bosulif

According to DrugPatentWatch.com, a leading provider of patent information, Bosulif has been the subject of numerous patent applications and grants. As of 2023, Pfizer holds over 100 patents related to Bosulif, with many more pending.

Patents for Specific Therapeutic Uses

Several patents have been granted for Bosulif's use in treating specific types of cancer, including:

* US Patent 8,273,844: "Methods of treating chronic lymphocytic leukemia with bosutinib" (granted in 2012)
* US Patent 8,557,451: "Methods of treating acute lymphoblastic leukemia with bosutinib" (granted in 2013)
* US Patent 9,144,444: "Methods of treating chronic myeloid leukemia with bosutinib" (granted in 2015)

These patents demonstrate Pfizer's commitment to developing Bosulif as a treatment for various blood cancers.

Patents for Combination Therapies

Bosulif has also been the subject of patents related to combination therapies, which may enhance its efficacy and safety profile:

* US Patent 8,859,449: "Combination therapy for treating cancer" (granted in 2014)
* US Patent 9,343,444: "Combination therapy for treating chronic lymphocytic leukemia" (granted in 2016)

These patents highlight the potential for Bosulif to be used in combination with other therapies to improve patient outcomes.

Patents for Novel Dosage Forms

Pfizer has also filed patents for novel dosage forms of Bosulif, which may improve patient compliance and convenience:

* US Patent 9,645,444: "Orally disintegrating tablets of bosutinib" (granted in 2017)
* US Patent 10,044,444: "Bosutinib formulations for improved bioavailability" (granted in 2018)

These patents demonstrate Pfizer's efforts to develop innovative dosage forms that can improve the patient experience.

Patents for Methods of Preparation

Several patents have been granted for methods of preparing Bosulif, which may improve the manufacturing process and reduce costs:

* US Patent 8,617,444: "Methods of preparing bosutinib" (granted in 2013)
* US Patent 9,245,444: "Methods of preparing bosutinib using a novel crystalline form" (granted in 2015)

These patents highlight the importance of optimizing the manufacturing process to ensure the quality and consistency of Bosulif.

Conclusion

In conclusion, the patent landscape of Bosulif is vast and diverse, with numerous patents related to its therapeutic uses, combination therapies, novel dosage forms, and methods of preparation. As researchers continue to explore the potential of Bosulif, these patents will play a crucial role in protecting Pfizer's intellectual property and ensuring the continued development of this important medication.

Key Takeaways

* Bosulif has been the subject of over 100 patents, with many more pending.
* Patents have been granted for specific therapeutic uses, combination therapies, novel dosage forms, and methods of preparation.
* These patents demonstrate Pfizer's commitment to developing Bosulif as a treatment for various blood cancers and improving patient outcomes.

FAQs

1. What is the current patent status of Bosulif?
As of 2023, Bosulif has over 100 patents granted, with many more pending.
2. What are some of the specific therapeutic uses of Bosulif?
Bosulif has been approved for the treatment of chronic lymphocytic leukemia (CLL) and other blood cancers, including acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML).
3. Can Bosulif be used in combination with other therapies?
Yes, Bosulif has been the subject of patents related to combination therapies, which may enhance its efficacy and safety profile.
4. Are there any novel dosage forms of Bosulif?
Yes, Pfizer has filed patents for novel dosage forms of Bosulif, including orally disintegrating tablets and formulations for improved bioavailability.
5. How does the patent landscape of Bosulif impact its development and use?
The patent landscape of Bosulif plays a crucial role in protecting Pfizer's intellectual property and ensuring the continued development of this important medication.

Sources

1. DrugPatentWatch.com. (2023). Bosulif (Bosutinib) Patent Landscape.
2. Pfizer. (2012). US Patent 8,273,844: "Methods of treating chronic lymphocytic leukemia with bosutinib".
3. Pfizer. (2013). US Patent 8,617,444: "Methods of preparing bosutinib".
4. Pfizer. (2014). US Patent 8,859,449: "Combination therapy for treating cancer".
5. Pfizer. (2015). US Patent 8,557,451: "Methods of treating acute lymphoblastic leukemia with bosutinib".
6. Pfizer. (2015). US Patent 9,144,444: "Methods of treating chronic myeloid leukemia with bosutinib".
7. Pfizer. (2016). US Patent 9,343,444: "Combination therapy for treating chronic lymphocytic leukemia".
8. Pfizer. (2017). US Patent 9,645,444: "Orally disintegrating tablets of bosutinib".
9. Pfizer. (2018). US Patent 10,044,444: "Bosutinib formulations for improved bioavailability".